Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rucaparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 15/20 | 1.00 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 9/20 | 0.65 |
| ▸ | PARP3 known ✓ | Q9Y6F1 | 1/20 | 0.65 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.65 |
| ▸ | TNKS | O95271 | 1/20 | 0.65 |
| ▸ | PGR | P06401 | 1/20 | 0.65 |
| ▸ | CDK1 | P06493 | 1/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.65 |
| ▸ | POLA1 | P09884 | 1/20 | 0.65 |
| ▸ | PIM1 | P11309 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.65 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.65 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.65 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.65 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rucaparib SCHEMBL29354703 | 1.00 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL22817574 | 1.00 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL30413070 | 0.83 | PARP1 (0.87) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL29351768 | 0.81 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL844585 | 0.81 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL29392034 | 0.80 | PARP1 (0.98) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL5746065 | 0.80 | PARP1 (0.98) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL844872 | 0.78 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL29379028 | 0.78 | PARP1 (1.00) | PARP1PARP2DYRK3TNKSPGR | |
| Rucaparib SCHEMBL5747917 | 0.78 | PARP1 (0.90) | PARP1PARP2DYRK3TNKSPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10130636-B2 | High dosage strength tablets of rucaparib | CLOVIS ONCOLOGY, INC. (US) | 2018-11-20 | — | — | US | claimed |
| US-20180200260-A1 | High Dosage Strength Tablets of Rucaparib | PHARMA& SCHWEIZ GMBH (CH) | 2018-07-19 | — | — | US | claimed |
| US-9987285-B2 | High dosage strength tablets of rucaparib | CLOVIS ONCOLOGY, INC. (US) | 2018-06-05 | — | — | US | claimed |
| EP-3182975-A1 | HIGH DOSAGE STRENGTH TABLETS OF RUCAPARIB | Clovis Oncology, Inc. (US) | 2017-06-28 | — | — | EP | claimed |
| US-20160051561-A1 | High Dosage Strength Tablets of Rucaparib | PHARMA& SCHWEIZ GMBH (CH) | 2016-02-25 | — | — | US | claimed |
| WO-2016028689-A1 | HIGH DOSAGE STRENGTH TABLETS OF RUCAPARIB | CLOVIS ONCOLOGY, INC. (US) | 2016-02-25 | — | — | WO | claimed |
| US-20190099430-A1 | High Dosage Strength Tablets of Rucaparib | PHARMA& SCHWEIZ GMBH (CH) | 2019-04-04 | — | — | US | disclosed |
| US-10130636-B2 | High dosage strength tablets of rucaparib | CLOVIS ONCOLOGY, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180200260-A1 | High Dosage Strength Tablets of Rucaparib | PHARMA& SCHWEIZ GMBH (CH) | 2018-07-19 | — | — | US | disclosed |
| US-9987285-B2 | High dosage strength tablets of rucaparib | CLOVIS ONCOLOGY, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-3182975-A1 | HIGH DOSAGE STRENGTH TABLETS OF RUCAPARIB | Clovis Oncology, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016028689-A1 | HIGH DOSAGE STRENGTH TABLETS OF RUCAPARIB | CLOVIS ONCOLOGY, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| US-20160051561-A1 | High Dosage Strength Tablets of Rucaparib | PHARMA& SCHWEIZ GMBH (CH) | 2016-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051561-A1 | High Dosage Strength Tablets of Rucaparib | PARP1, PARP11, PARP16 | PARP1 1/4885PARP2 23/4885PARP3 40/4885 |
| US-10130636-B2 | High dosage strength tablets of rucaparib | PARP1, PARP11, PARP16 | PARP1 1/4885PARP2 23/4885PARP3 40/4885 |
| US-20180200260-A1 | High Dosage Strength Tablets of Rucaparib | PARP1, PARP11, PARP16 | PARP1 1/4885PARP2 23/4885PARP3 40/4885 |
| US-20190099430-A1 | High Dosage Strength Tablets of Rucaparib | PARP1, PARP11, PARP16 | PARP1 1/4885PARP2 23/4885PARP3 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.